PLATO-11 Gives Clinicians a Fast, Validated Way to Track Sleep Apnea Treatment

Obstructive sleep apnea affects tens of millions of adults and carries significant long-term health consequences including cardiovascular disease, cognitive decline, and metabolic dysfunction. Despite the availability of effective treatments, clinical practice has lacked a standardized, validated patient-reported outcome tool specifically designed to monitor OSA symptom response across the treatment lifecycle — a gap that PLATO-11 now addresses.

The development process followed FDA guidance for PRO measures and used a rigorous mixed-methods, multiphase design. In Part 1, concept elicitation and cognitive interviews with OSA patients identified the most clinically meaningful symptoms and daily impacts. Part 2 involved pilot testing a draft instrument at 10 American Academy of Sleep Medicine (AASM)-accredited sleep centers to refine item wording, recall period, and response formats. Part 3 conducted full psychometric validation using longitudinal online surveys in 560 adults diagnosed with OSA and 40 healthy controls, employing exploratory factor analysis, Rasch modeling, test-retest reliability testing, internal consistency analysis, construct validity assessment, and responsiveness-to-change evaluation.

The final 11-item tool demonstrated exceptional measurement properties: internal consistency (Cronbach's α = 0.94), test-retest reliability (intraclass correlation coefficients of 0.91–0.97), and moderate-to-strong correlations with established OSA and sleepiness measures supporting construct validity. PLATO-11 scores successfully discriminated between different OSA severity levels and body mass index groups. The tool was also responsive to clinically meaningful symptom improvement, and clinically important difference thresholds were established to aid interpretation. Mean completion time was under 4 minutes.

For clinicians and researchers, PLATO-11 offers several practical advantages. It is publicly available, works in both paper and electronic formats, has been translated into Spanish, and covers both the nighttime respiratory disturbances and daytime sequelae (such as sleepiness and fatigue) that patients consistently report as their primary concerns. The 7-day recall period balances ecological validity with recall accuracy. These features make it suitable for routine clinical monitoring across initial diagnosis, treatment initiation, and long-term follow-up visits.

Caveats include the online survey methodology used for psychometric validation, which may not fully represent clinical populations seen in sleep centers. The study sample characteristics and generalizability beyond English- and Spanish-speaking adults remain to be confirmed. Additionally, while clinically important difference thresholds were established, further prospective validation in diverse real-world clinical settings will strengthen the evidence base for interpreting PLATO-11 score changes.